• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

    9/3/25 4:30:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYGN alert in real time by email

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight® Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual (TAU).

    Specifically, compared to TAU, patients in the GeneSight arm were:

    • 41% more likely to achieve remission.
    • 30% more likely to achieve response.

    "This meta-analysis summarizes the clinical evidence of the GeneSight test, demonstrating superiority over treatment as usual—which often involves repeated medication trials," said Sagar V. Parikh, M.D., FRCPC, study author, professor of psychiatry at the University of Michigan, associate director of the University of Michigan Depression Center. "This study found that the GeneSight test can be a powerful tool to augment a clinician's knowledge, experience and passion for their patients' recovery."

    The large-scale data analysis—merging data over many independent studies—provides evidence of the clinical utility of the GeneSight Psychotropic test for patients with MDD who have experienced at least one treatment failure.

    "Depression is not just a mental health issue—it's a public health priority. If we want to improve overall outcomes and enhance quality of life, we must treat depression with the same urgency and resources as any other chronic condition," said Dale Muzzey, PhD, chief scientific officer, Myriad Genetics. "This meta-analysis adds to our confidence in the clinical validity and utility of the GeneSight test."

    Myriad Genetics plans to submit this data to payers as part of ongoing efforts to increase patient access to the GeneSight test and help patients achieve remission from depression.

    About the Meta-Analysis

    The study analyzed six prospective, controlled trials to assess the impact of the GeneSight Psychotropic test on clinical outcomes in a total of 3,532 unique adults with MDD who had at least one prior treatment failure. The trials included in the meta-analysis incorporated the widely used depression questionnaires, the Hamilton Depression Rating Scale (HAM-D17) and the Patient Health Questionnaire (PHQ-9), to assess severity of depression symptoms. Response was defined as a 50% or greater improvement in depression scores from baseline to endpoint. Remission was defined as a score of seven or less on the HAM-D17 or a score of five or less on the PHQ-9.

    1 Pine Rest (Winner et al., 2013), Hamm (Hall-Flavin et al., 2012), La Crosse (Hall-Flavin et al., 2013), GUIDED (Greden et al., 2019), PRIME Care (Oslin et al., 2022), GAPP-MDD (Tiwari et al., 2022)

    About the GeneSight® Test

    The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patient's genes may impact how they metabolize and/or respond to certain psychiatric medications. It is designed to provide information that may help reduce the trial-and-error process that often takes place when patients are prescribed certain mental health medications. Learn more at www.genesight.com.

    About Myriad Genetics 

    Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the meta-analysis and how it adds to the company's confidence in the clinical validity and utility of the GeneSight test, as well as the company's plans to submit data from the meta-analysis to payors as part of ongoing efforts to increase patient access to the GeneSight test and help patients achieve remission from depression. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. 

    Investor Contact 

    Matt Scalo 

    (801) 584-3532 

    [email protected] 

    Media Contact 

    Kate Schraml

    (224) 875-4493

    [email protected]



    Primary Logo

    Get the next $MYGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYGN

    DatePrice TargetRatingAnalyst
    5/21/2025$6.00Sector Outperform → Sector Perform
    Scotiabank
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    4/9/2025Buy → Neutral
    Guggenheim
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    2/12/2025$29.00Buy
    Craig Hallum
    12/10/2024$18.00Neutral
    UBS
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $MYGN
    SEC Filings

    View All

    Myriad Genetics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MYRIAD GENETICS INC (0000899923) (Filer)

    8/18/25 8:31:42 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SCHEDULE 13G filed by Myriad Genetics Inc.

    SCHEDULE 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    8/12/25 4:06:10 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by Myriad Genetics Inc.

    10-Q - MYRIAD GENETICS INC (0000899923) (Filer)

    8/6/25 6:09:51 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Fox Jennifer Lynne covered exercise/tax liability with 4,435 shares, decreasing direct ownership by 4% to 120,481 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    9/4/25 4:14:17 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Wheeler Benjamin Richard was granted 60,000 shares, increasing direct ownership by 170% to 95,210 units (SEC Form 4)

    4 - MYRIAD GENETICS INC (0000899923) (Issuer)

    8/19/25 5:24:18 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Wheeler Benjamin Richard claimed ownership of 35,210 shares (SEC Form 3)

    3 - MYRIAD GENETICS INC (0000899923) (Issuer)

    8/19/25 5:19:13 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

    SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad's molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). One of the goals of this study was to determine whether patients with oligometastatic ccRCC could benefit from incorporating ultrasensitive MRD testing into their care. The study demonstrated that circulating tumor DNA (ctDNA) levels were associated with patients' response to metastasis-directed radiation therapy (MDT).

    9/4/25 7:00:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

    SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight® Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual (TAU). Specifically, compared to TAU, patients in the GeneSight arm were: 41% more likely to achieve remission.30% more likely to achieve response. "

    9/3/25 4:30:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

    SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The Wells Fargo Healthcare Conference with a fireside chat on Thursday, Sept. 4 at 3:45pm ET.The Morgan Stanley Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 10 at 7:45am ET. Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com. About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and we

    8/27/25 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Myriad Genetics downgraded by Scotiabank with a new price target

    Scotiabank downgraded Myriad Genetics from Sector Outperform to Sector Perform and set a new price target of $6.00

    5/21/25 8:40:26 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics downgraded by Wolfe Research

    Wolfe Research downgraded Myriad Genetics from Outperform to Peer Perform

    5/8/25 8:27:12 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00

    5/7/25 8:36:31 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MYGN
    Leadership Updates

    Live Leadership Updates

    View All

    $MYGN
    Financials

    Live finance-specific insights

    View All

    $MYGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

    SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scott Leffler, who has served as Chief Financial Officer since January 2024, will transition to a consulting role serving the CEO and the Board of D

    8/18/25 8:30:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

    SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies. "Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric

    4/7/25 8:00:00 AM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Announces Senior Leadership Transition

    SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year. "Since joining Myriad in December 2023, Sam has played an integral role in sh

    2/24/25 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum

    Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year.Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-over-year, benefiting from product mix, improving average revenue per test trends, and greater laboratory efficiencies. Second quarter 2025 GAAP net loss of $330.5 million, or $(3.57) per share, reflecting non-cash impairment charges

    8/5/25 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025

    SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the second quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registerin

    7/29/25 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

    Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

    5/6/25 4:05:00 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

    SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

    11/14/24 4:16:31 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Myriad Genetics Inc.

    SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    5/1/24 4:21:33 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Myriad Genetics Inc.

    SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

    4/25/24 4:18:40 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care